Therapeutic antibodies and alternative formats against SARS-CoV-2

Antiviral Res. 2024 Feb 1;223:105820. doi: 10.1016/j.antiviral.2024.105820. Online ahead of print.ABSTRACTThe COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) heavily burdened the entire world. Despite a prompt generation of vaccines and therapeutics to confront infection, the virus remains a threat. The ancestor viral strain has evolved into several variants of concern, with the Omicron variant now having many distinct sublineages. Consequently, most available antibodies targeting the spike went obsolete and thus new therapies or therapeutic formats are needed. In this review we focus on antibody targets, provide an overview of the therapeutic progress made so far, describe novel formats being explored, and lessons learned from therapeutic antibodies that can enhance pandemic preparedness.PMID:38307147 | DOI:10.1016/j.antiviral.2024.105820
Source: Antiviral Research - Category: Virology Authors: Source Type: research